ENMistletoe therapy in Germany, injections of white mistletoe extract given alongside cancer treatment and not instead of it, is so widely known that patients starting chemotherapy or radiotherapy are often told by friends to “add mistletoe, everyone in Germany uses it”. So the question is fair.
Below: what the preparation is, what is proven and what is not, who it is discussed for, how a course runs and why it never replaces the main treatment. The broader topic is integrative oncology.
What mistletoe therapy is
Mistletoe therapy uses an extract of European white mistletoe (Viscum album), a semi-parasitic plant growing on trees. It is injected under the skin, usually several times a week, with the dose raised step by step.
The method comes from early 20th-century anthroposophic medicine, rooted in a worldview rather than in natural science. Today several manufacturers make mistletoe preparations, whose composition depends on the host tree and extraction method.
The best-studied ingredients are lectins and viscotoxins: in simple terms, proteins that kill tumour cells and stimulate immune cells in laboratory experiments. But a laboratory effect is not yet an effect in patients.
What studies and German guidelines say
Studies and German guidelines agree that longer survival and tumour shrinkage have not been reliably shown. Results contradict each other, and trials are often small, frequently without a control group or blinding: participants know they are getting mistletoe, not least because the injection site often turns red.
The German S3 guideline on complementary medicine in cancer care is cautious: subcutaneous mistletoe extract can be considered to improve quality of life in patients with solid tumours, an open recommendation and the mildest of three grades. It does not recommend infusions into a vein or injections straight into the tumour: its assessments rest only on randomised trials in cancer care, and the quality-of-life data come from injections under the skin. For these routes, usable data are even scarcer.
The US National Cancer Institute’s summary on mistletoe extracts says in plain words that research continues, that findings so far need caution because many studies were small or poorly designed, and that anyone considering mistletoe should discuss it with their doctor. So it can be raised as an addition, never as a substitute for surgery, chemotherapy, radiotherapy or immunotherapy. Hyperthermia for cancer is another add-on method with its own page.
Who mistletoe therapy is discussed for — and who not
Mistletoe therapy is mostly discussed for solid tumours, those of organs rather than the blood, to support wellbeing, appetite and sleep during and after demanding treatment. German statutory health insurance covers mistletoe preparations under defined conditions: only in palliative care, when the cancer can no longer be cured, and only to improve quality of life.
Doctors are cautious with an allergy to the preparation, acute infections, high fever and some brain tumours and blood cancers: some manufacturers warn about these, but not all. The oncologist decides.
Combining mistletoe with immunotherapy or targeted drugs, medicines aimed at specific features of tumour cells, is a separate conversation with the treating doctor. For checkpoint inhibitors, one group of immunotherapy drugs, the S3 guideline has so far seen no sign of more serious side effects, but information on interactions differs between mistletoe preparations. So it is never added on one’s own; see cancer immunotherapy.
How a course runs and what reactions to expect
A course starts with a choice: an oncologist or a doctor experienced in complementary medicine selects the preparation and schedule. The first injections are given under supervision, then the patient learns to inject at home, which many manage after instruction and some practice.
Expected reactions are redness and a small lump at the injection site, a slight temperature and a flu-like feeling; early in a course, the local reaction and slight temperature are almost the rule. Call the doctor for a strong allergic reaction, high fever or a large skin inflammation around the injection site.
The duration is set by the doctor according to wellbeing and the main treatment; there is no standard length, and manufacturers even disagree on breaks. Mistletoe is not injected indefinitely without review: each new stage of the main treatment is a reason to decide again.
Frequently asked questions
Can mistletoe therapy cure cancer?
No. There is no generally accepted scientific evidence that mistletoe extract cures cancer, and longer survival or tumour shrinkage has not been reliably shown. The S3 guideline only says that subcutaneous mistletoe can be considered for quality of life in solid tumours. It replaces neither surgery nor chemotherapy, radiotherapy or immunotherapy.
Can mistletoe therapy be given during chemotherapy or radiotherapy?
Yes, it is usually discussed as an addition to such treatment, but the oncologist in charge of the main treatment decides. All doctors involved, including the family doctor, should know about it. People taking part in a clinical trial are usually not given mistletoe, so as not to affect the trial conditions.
Can mistletoe therapy be continued at home?
Yes, if the doctor agrees: many patients inject themselves after instruction, or a doctor or nurse gives the injections, under the skin of the abdomen, thigh or upper arm. Before leaving, get a written schedule with the doses and know whom to call if a strong reaction occurs.
How long does a course of mistletoe therapy last?
There is no standard duration: how often, how long and at what dose to inject depends on the preparation and the doctor’s advice, and manufacturers differ on breaks between cycles. The doctor goes by the patient’s wellbeing and the main treatment and, whenever that treatment changes, decides again whether mistletoe is still needed.
How AlenMed arranges advice on mistletoe therapy in Germany
AlenMed arranges advice on mistletoe therapy as part of the discussion about the main treatment, which comes first. Reports, histology and scans are translated, and an oncologist at a partner hospital reviews the treatment plan; the mistletoe question is asked in the same request, not separately. For cancer care as a whole, see cancer treatment in Germany.
If the oncologist considers mistletoe appropriate, it is clarified in advance who prescribes it, where the first injections are given, how to continue at home after returning and which documents and prescriptions are needed. If useful, a video consultation takes place before travelling; the hospital sends its cost estimate, and an interpreter attends appointments. AlenMed’s office is in Munich; partner hospitals are all over Germany.
This material is for reference only and is not an offer. Mistletoe therapy does not replace cancer treatment, and the treatment plan is decided by a doctor after an in-person consultation.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
